CONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM
|
|
- Dominick Moore
- 5 years ago
- Views:
Transcription
1 RAPID COMMUNICATION CME ARTICLE CONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM ALAN W. PARTIN, LESLIE A. MANGOLD, DANA M. LAMM, PATRICK C. WALSH, JONATHAN I. EPSTEIN, AND JAY D. PEARSON ABSTRACT Objectives. We previously presented nomograms combining preoperative serum prostate-specific antigen (), clinical (TNM) stage, and biopsy Gleason score to provide the likelihood of various final pathologic stages at radical retropubic prostatectomy. The data for the original nomograms were collected from men treated between 1982 and During the past 10 years, the stage at presentation has shifted, with more men presenting with Stage T1c, Gleason score 5 to 6, and serum levels less than 10.0 ng/ml. In this work, we update the Partin Tables with a more contemporary cohort of men treated since 1994 and with revised and Gleason categories. Methods. Multinomial log-linear regression analysis was used to estimate the likelihood of organ-confined disease, extraprostatic extension, seminal vesicle or lymph nodal status from the preoperative stratified as 0 to 2.5, 2.6 to 4.0, 4.1 to 6.0, 6.1 to 10.0, and greater than 10 ng/ml, clinical (AJCC-TNM, 1992) stage (T1c, T2a, T2b, or T2c), and biopsy Gleason score stratified as 2 to 4, 5 to 6, 3 4 7, 4 3 7, or 8 to 10 among 5079 men treated with prostatectomy (without neoadjuvant therapy) between 1994 and 2000 at Johns Hopkins Hospital. The average age was 58 years. Results. In this cohort, more than 60% had T1c, more than 75% had Gleason score of 6, more than 70% had greater than 2.5 and less than 10.0 ng/ml, and more than 60% had organ-confined disease. Nomograms of the robust estimated likelihoods and 95% confidence intervals were developed from 1000 bootstrap analyses. The probability of organ-confined disease improved across the groups, and further stratification of the Gleason score and level allowed better differentiation of individual patients. Conclusions. These updated Partin Tables were generated to reflect the trends in presentation and pathologic stage for men newly diagnosed with clinically localized prostate cancer at our institution. Clinicians can use these nomograms to counsel individual patients and help them make important decisions regarding their disease. UROLOGY 58: , , Elsevier Science Inc. This study was supported by Prostate SPORE grant CA and NCI Early Detection Research Network (EDRN) grant UO1 CA From the James Buchanan Brady Urological Institute and Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland and Merck Research Laboratories, Rahway, New Jersey Reprint requests: Alan W. Partin, M.D., Ph.D., Brady Urological Institute, Johns Hopkins Hospital, 600 North Wolfe Street, Marburg 205A, Baltimore, MD Submitted: August 1, 2001, accepted (with revisions): August 16, 2001 The American Cancer Society reported this year a continued decrease in prostate cancer death rates, with an estimate that 75% of newly diagnosed patients this year will present with either local or regional disease. 1 This trend or stage migration, whether the result of improved early detection programs or a change in the biology of the disease, has nonetheless resulted in a dramatic shift in the stage at presentation for men newly diagnosed with prostate cancer. More men are presenting with serum prostate-specific antigen () levels between 2.5 and 10.0 ng/ml, predominately Gleason scores of 6, normal digital rectal examinations (clinical Stage T1c), and, most importantly, with localized organ-confined disease (more than 75% in our recent series). Our present staging algorithms, 2 4 which were based on data collected primarily from cases treated before 1995, less accurately reflect the presentation of the contemporary cohort of men presenting today with prostate cancer. In this work, we update the Partin Tables 2001, ELSEVIER SCIENCE INC /01/$20.00 ALL RIGHTS RESERVED PII S (01)
2 with a more contemporary cohort of men treated since 1994 with revised and Gleason categories. MATERIAL AND METHODS PATIENTS Between 1994 and 2000, 5079 men with clinically localized prostate cancer and no neoadjuvant hormonal or radiation therapy underwent radical retropubic prostatectomy (RRP) and a staging pelvic lymphadenectomy at the Johns Hopkins Hospital by 1 of 11 attending surgeons. INCLUSION CRITERIA Men enrolled in this cohort had (a) a preoperative monoclonal serum level on an ambulatory basis before RRP and at least 4 weeks after the prostate biopsy, (b) a biopsy histologic grade (Gleason score), and (c) a clinical stage assigned by the attending physician (AJCC-TNM, 1992) of T1c, T2 (a-c). Men were excluded because of a lack of this information or if they received preoperative neoadjuvant hormonal therapy. Although a very rare occurrence (0.25%), men with grossly positive pelvic lymph nodes who did not undergo surgery were also excluded from this analysis. PATHOLOGIC EXAMINATION All pelvic lymph nodes removed at surgery were sectioned and examined for the presence of cancer. Likewise, the surgical specimen, including the prostate and seminal vesicles, was analyzed and the pathologic stage determined as organ-confined if all cancer was confined within the prostate, extraprostatic extension if cancer was evident outside the prostate and the seminal vesicles and the pelvic lymph nodes were free from metastatic disease, positive seminal vesicle involvement if the tumor invaded the muscular wall of the seminal vesicle without lymph nodal involvement, and lymph node involvement if the pelvic lymph nodes were involved with cancer. STATISTICAL ANALYSIS Baseline-category multinomial log-linear regression analysis 5 was performed simultaneously for the four outcomes. The predictor variables were serum total levels before surgery, which were categorically divided into 0 to 2.5, 2.6 to 4.0, 4.1 to 6.0, 6.1 to 10, and more than 10.0 ng/ml, TNM clinical stage (AJCC 1992) as T1c, T2a, T2b, or T2c (categorical), and biopsy Gleason score sum divided categorically as 2 to 4, 5 to 6, 3 4 7, 4 3 7, and 8 to 10. S-Plus for Windows software was used to perform the multinomial log-linear regression analysis. The nomograms were constructed from the robust predicted probabilities and the 95% confidence intervals for the final model that were obtained by repeating the analysis on 1000 bootstrap samples 6 from the original cohort. The bootstrap analyses were performed in S-Plus for Windows. RESULTS PARTICIPANT DEMOGRAPHICS In the study, 5079 men, average age years (range 42 to 74) who fit the enrollment criteria, were consecutively enrolled. Ninety percent of the men were white and 6% African American. Within the groups, 7%, 10%, 27%, 35%, and 21% were within the 0 to 2.5, 2.6 to 4.0, 4.1 to 6.0, 6.1 to 10, and more than 10.0 ng/ml groups, respectively. Biopsy Gleason grades (sum) demonstrated 0.6%, 79%, 13%, 4.4%, and 3% with a Gleason score of 2 to 4, 5 to 6, 3 4 7, 4 3 7, and 8 to 10, respectively. Seventy-five percent of the biopsy Gleason scores were The clinical stage was T1c, T2a, T2b, and T2c in 63%, 32%, 11%, and 3%, respectively. The final pathologic stage demonstrated that 64%, 30%, 4%, and 2% had organ-confined disease, extraprostatic extension, seminal vesicle involvement, or lymph node involvement, respectively. NOMOGRAMS Tables I to IV demonstrate the probability of presenting with the various pathologic stages when the preoperative serum, biopsy Gleason histologic grade, and clinical stage (AJCC 1992) are known. The updated nomograms have modified groups and Gleason sum groups. The groups are divided into five categories: 0 to 2.5, 2.6 to 4.0, 4.1 to 6.0, 6.1 to 10, and more than 10.0 ng/ml to further substratify men with respect to their level. Additionally, we substratified the Gleason scores into modified groups based on the risk of recurrence. In previous work from our institution, Kaplan-Meier actuarial survival curves (data not shown) for men with follow-up of more than 8 years demonstrated that biochemical progression-free survival for tumors with Gleason score 2 to 4 were similar, as were those with a within-the-groups Gleason score of 5 to 6 and 8 to Thus, these Gleason scores were subgrouped as 2 to 4, 5 to 6, or 8 to 10. Likewise, previous data have also demonstrated that Gleason sums of and behave differently and warrant substratification. 8 Like our previous nomograms,, Gleason score (biopsy), and clinical stage contributed significantly to the prediction of pathologic stage in the multinomial log-linear progression (P 0.001). Also, as seen in our previous nomograms, similar results were seen when was used as a continuous variable and all two-way and three-way interactions were tested and added little to the statistical significance of the final model (P 0.05). The final model contained only the main effects, and the combination of the three variables predicted better than any single variable. The medians (95% confidence intervals [CIs]) of the predicted probabilities from the multinomial log-linear regression analysis of 1000 bootstrap samples from the original study group are presented in the nomograms (Tables I to IV). The numbers within each cell of the nomogram represent the percentage of likelihood of a given pathologic stage based on the regression of all three variables combined. For example, a man with a preoperative serum level of 2.7 ng/ml and a biopsy Gleason score of 844 UROLOGY 58 (6), 2001
3 TABLE I. Clinical Stage T1c (nonpalpable, elevated) Organ confined 95 (89 99) 90 (88 93) 79 (74 85) 71 (62 79) 66 (54 76) Extraprostatic extension 5 (1 11) 9 (7 12) 17 (13 23) 25 (18 34) 28 (20 38) Seminal vesicle ( ) 0(0 1) 2 (1 5) 2 (1 5) 4 (1 10) Lymph node ( ) 1(0 2) 1 (0 4) 1 (0 4) Organ confined 92 (82 98) 84 (81 86) 68 (62 74) 58 (48 67) 52 (41 63) Extraprostatic extension 8 (2 18) 15 (13 18) 27 (22 33) 37 (29 46) 40 (31 50) Seminal vesicle ( ) 1(0 1) 4 (2 7) 4 (1 7) 6 (3 12) Lymph node ( ) 1(0 2) 1 (0 3) 1 (0 4) Organ confined 90 (78 98) 80 (78 83) 63 (58 68) 52 (43 60) 46 (36 56) Extraprostatic extension 10 (2 22) 19 (16 21) 32 (27 36) 42 (35 50) 45 (36 54) Seminal vesicle ( ) 1(0 1) 3 (2 5) 3 (1 6) 5 (3 9) Lymph node ( ) 0(0 1) 2 (1 3) 3 (1 5) 3 (1 6) Organ confined 87 (73 97) 75 (72 77) 54 (49 59) 43 (35 51) 37 (28 46) Extraprostatic extension 13 (3 27) 23 (21 25) 36 (32 40) 47 (40 54) 48 (39 57) Seminal vesicle ( ) 2(2 3) 8 (6 11) 8 (4 12) 13 (8 19) Lymph node ( ) 0(0 1) 2 (1 3) 2 (1 4) 3 (1 5) 10.0 Organ confined 80 (61 95) 62 (58 64) 37 (32 42) 27 (21 34) 22 (16 30) Extraprostatic extension 20 (5 39) 33 (30 36) 43 (38 48) 51 (44 59) 50 (42 59) Seminal vesicle ( ) 4(3 5) 12 (9 17) 11 (6 17) 17 (10 25) Lymph node ( ) 2(1 3) 8 (5 11) 10 (5 17) 11 (5 18) KEY: prostate-specific antigen. TABLE II. Clinical Stage T2a (palpable < 1 2 of one lobe) Organ confined 91 (79 98) 81 (77 85) 64 (56 71) 53 (43 63) 47 (35 59) Extraprostatic extension 9 (2 21) 17 (13 21) 29 (23 36) 40 (30 49) 42 (32 53) Seminal vesicle ( ) 1(0 2) 5 (1 9) 4 (1 9) 7 (2 16) Lymph node ( ) 0(0 1) 2 (0 5) 3 (0 8) 3 (0 9) Organ confined 85 (69 96) 71 (66 75) 50 (43 57) 39 (30 48) 33 (24 44) Extraprostatic extension 15 (4 31) 27 (23 31) 41 (35 48) 52 (43 61) 53 (44 63) Seminal vesicle ( ) 2(1 3) 7 (3 12) 6 (2 12) 10 (4 18) Lymph node ( ) 0(0 1) 2 (0 4) 2 (0 6) 3 (0 8) Organ confined 81 (63 95) 66 (62 70) 44 (39 50) 33 (25 41) 28 (20 37) Extraprostatic extension 19 (5 37) 32 (28 36) 46 (40 52) 56 (48 64) 58 (49 66) Seminal vesicle ( ) 1(1 2) 5 (3 8) 5 (2 8) 8 (4 13) Lymph node ( ) 1(0 2) 4 (2 7) 6 (3 11) 6 (2 12) Organ confined 76 (56 94) 58 (54 61) 35 (30 40) 25 (19 32) 21 (15 28) Extraprostatic extension 24 (6 44) 37 (34 41) 49 (43 54) 58 (51 66) 57 (48 65) Seminal vesicle ( ) 4(3 5) 13 (9 18) 11 (6 17) 17 (11 26) Lymph node ( ) 1(0 2) 3 (2 6) 5 (2 8) 5 (2 10) 10.0 Organ confined 65 (43 89) 42 (38 46) 20 (17 24) 14 (10 18) 11 (7 15) Extraprostatic extension 35 (11 57) 47 (43 52) 49 (43 55) 55 (46 64) 52 (41 62) Seminal vesicle ( ) 6(4 8) 16 (11 22) 13 (7 20) 19 (12 29) Lymph node ( ) 4(3 7) 14 (9 21) 18 (10 27) 17 (9 29) KEY: prostate-specific antigen and a nonpalpable (Stage T1c) digital rectal examination has an 84% probability of organ-confined disease. A man with a of 11.4 ng/ml and a biopsy Gleason score of 8 with a large palpable tumor (Stage T2c) has only a 6% chance of organ-confined disease at surgery. COMMENT The presentation of men with localized prostate cancer during the past 10 to 20 years has changed greatly. More men are presenting with well to moderately differentiated tumors (Gleason 4 to 6), UROLOGY 58 (6),
4 TABLE III. Clinical Stage T2b (palpable > 1 2 of one lobe, not on both lobes) Organ confined 88 (73 97) 75 (69 81) 54 (46 63) 43 (33 54) 37 (26 49) Extraprostatic extension 12 (3 27) 22 (17 28) 35 (28 43) 45 (35 56) 46 (35 58) Seminal vesicle ( ) 2(0 3) 6 (2 12) 5 (1 11) 9 (2 20) Lymph node ( ) 1(0 2) 4 (0 10) 6 (0 14) 6 (0 16) Organ confined 80 (61 95) 63 (57 69) 41 (33 48) 30 (22 39) 25 (17 34) Extraprostatic extension 20 (5 39) 34 (28 40) 47 (40 55) 57 (47 67) 57 (46 68) Seminal vesicle ( ) 2(1 4) 9 (4 15) 7 (3 14) 12 (5 22) Lymph node ( ) 1(0 2) 3 (0 8) 4 (0 12) 5 (0 14) Organ confined 75 (55 93) 57 (52 63) 35 (29 40) 25 (18 32) 21 (14 29) Extraprostatic extension 25 (7 45) 39 (33 44) 51 (44 57) 60 (50 68) 59 (49 69) Seminal vesicle ( ) 2(1 3) 7 (4 11) 5 (3 9) 9 (4 16) Lymph node ( ) 2(1 3) 7 (4 13) 10 (5 18) 10 (4 20) Organ confined 69 (47 91) 49 (43 54) 26 (22 31) 19 (14 25) 15 (10 21) Extraprostatic extension 31 (9 53) 44 (39 49) 52 (46 58) 60 (52 68) 57 (48 67) Seminal vesicle ( ) 5(3 8) 16 (10 22) 13 (7 20) 19 (11 29) Lymph node ( ) 2(1 3) 6 (4 10) 8 (5 14) 8 (4 16) 10.0 Organ confined 57 (35 86) 33 (28 38) 14 (11 17) 9 (6 13) 7 (4 10) Extraprostatic extension 43 (14 65) 52 (46 56) 47 (40 53) 50 (40 60) 46 (36 59) Seminal vesicle ( ) 8(5 11) 17 (12 24) 13 (8 21) 19 (12 29) Lymph node ( ) 8(5 12) 22 (15 30) 27 (16 39) 27 (14 40) KEY: prostate-specific antigen. TABLE IV. Clinical Stage T2c (palpable on both lobes) Organ confined 86 (71 97) 73 (63 81) 51 (38 63) 39 (26 54) 34 (21 48) Extraprostatic extension 14 (3 29) 24 (17 33) 36 (26 48) 45 (32 59) 47 (33 61) Seminal vesicle ( ) 1(0 4) 5 (1 13) 5 (1 12) 8 (2 19) Lymph node ( ) 1(0 4) 6 (0 18) 9 (0 26) 10 (0 27) Organ confined 78 (58 94) 61 (50 70) 38 (27 50) 27 (18 40) 23 (14 34) Extraprostatic extension 22 (6 42) 36 (27 45) 48 (37 59) 57 (44 70) 57 (44 70) Seminal vesicle ( ) 2(1 5) 8 (2 17) 6 (2 16) 10 (3 22) Lymph node ( ) 1(0 4) 5 (0 15) 7 (0 21) 8 (0 22) Organ confined 73 (52 93) 55 (44 64) 31 (23 41) 21 (14 31) 18 (11 28) Extraprostatic extension 27 (7 48) 40 (32 50) 50 (40 60) 57 (43 68) 57 (43 70) Seminal vesicle ( ) 2(1 4) 6 (2 11) 4 (1 10) 7 (2 15) Lymph node ( ) 3(1 7) 12 (5 23) 16 (6 32) 16 (6 33) Organ confined 67 (45 91) 46 (36 56) 24 (17 32) 16 (10 24) 13 (8 20) Extraprostatic extension 33 (9 55) 46 (37 55) 52 (42 61) 58 (46 69) 56 (43 69) Seminal vesicle ( ) 5(2 9) 13 (6 23) 11 (4 21) 16 (6 29) Lymph node ( ) 3(1 6) 10 (5 18) 13 (6 25) 13 (5 26) 10.0 Organ confined 54 (32 85) 30 (21 38) 11 (7 17) 7 (4 12) 6 (3 10) Extraprostatic extension 46 (15 68) 51 (42 60) 42 (30 55) 43 (29 59) 41 (27 57) Seminal vesicle ( ) 6(2 12) 13 (6 24) 10 (3 20) 15 (5 28) Lymph node ( ) 13 (6 22) 33 (18 49) 38 (20 58) 38 (20 59) KEY: prostate-specific antigen. levels less than 10.0 ng/ml, and nonpalpable (Stage T1c) disease. This dramatic change in presentation, which may be due to and better screening strategies, has nonetheless caused a major stage migration for prostate cancer, with nearly 60% of newly diagnosed cases presenting with localized or regional disease. 1 Our methods for predicting the pathologic stage, which were primarily developed from data collected from men treated before this stage migration, 2 4 must also evolve to allow us to make accurate predictions for men newly diagnosed with prostate cancer. For this reason, we have updated our nomograms ( Partin Tables ) to better represent the demographic, clini- 846 UROLOGY 58 (6), 2001
5 cal, and biochemical data of men presenting with prostate cancer in Like our previous tables, simple, easily obtainable variables were used (serum, biopsy Gleason score, and clinical stage [AJCC TNM-1992]) and combined into simple-touse tables. Several patients and physicians who used the previous nomograms 2 suggested that an individual with a serum level of 4.1 ng/ml must have a higher probability of organ-confined disease than an individual with a of 10.1 ng/ml with the same stage and Gleason score (eg, T2c and 3 4 7). Intuitively, this seemed obvious; however, the previous tables lumped these men into the same group and provided limited differentiation with respect to the likelihood of the various pathologic stages. In the previous (1997) nomograms, both men would have had a likelihood of organ-confined disease of 25%; the new (2001) nomograms provide the first man with a likelihood of organconfined disease of 31% (95% CI 23% to 41%). The second would have only an 11% (95% CI 7% to 17%) chance of organ-confined disease and no overlap in the confidence intervals. Additionally, two men with similar levels (eg, 5.2 ng/ml) and similar digital rectal examination results (eg, T2a) might have a biopsy Gleason score of (44% chance of organ-confined disease, 95% CI 39% to 50%) compared with a man with a biopsy Gleason score of who has only a 33% chance of organ-confined disease, 95% CI 25% to 41% (little overlap in confidence intervals). The further stratification of the Gleason groups and the groups are provided to better capture the actual probabilities of the various pathologic stages for the individual patient. Since we presented our 1997 updated nomograms, investigators at the Mayo Clinic have independently evaluated this method of stage prediction on their cohort of patients and provided excellent validation of this method. 9 Others have suggested the incorporation of race, 10 biopsy information such as the number of cores or the percentage of cores involved, 11 or use of transrectal ultrasound staging, 12 or nuclear chromatin texture characteristics 13 into similar staging models. Although these suggestions may improve the prediction of the pathologic stage, they make the use of simple tables more cumbersome because of the increased number of variables and have yet to be validated in large cohorts of patients. Large numbers of variables (greater than three or four) will require the use of neural networks for stage prediction and are presently being evaluated for this purpose. 14 Additionally, within this contemporary cohort, the numbers of biopsies with Gleason scores 2 to 4 are very limited and the probabilities should be interpreted with caution. At our institution, a Gleason score of 2 to 4 on prostate biopsy is no longer given. 15 With only 6% African-American men in this cohort, the utility of these tables for African-American men is questionable. Within the only subgroup of African-American men with enough numbers for statistical analysis (T1c, 3 3 6, 6.0 to 10.0 ng/ml, n 38), the rate of organ-confined cancer was 81% for all men, 81% for white men, and 80% for African-American men. Thus, we continue to caution use of these tables for African-American men until they can be validated in other cohorts with larger numbers of African- American men. The primary value of these updated Partin Tables will be for counseling patients regarding the probability of their tumor being a specific pathologic stage, rather than a strict decision-making tool. The nomograms may help patients and their treating physicians make informed decisions based on the probability of a pathologic stage, the individual patient s risk tolerance, and the values they place on the various potential outcomes. In addition, the use of these nomograms may aid in the rational selection of patients to undergo definitive therapy for prostate cancer with the hope of further improving the numbers and percentage of cancers that receive effective therapy that will cure the disease. CONCLUSIONS We have updated our nomograms for predicting pathologic stage for prostate cancer with a more contemporary cohort of men treated between 1994 and The new nomograms combine, biopsy Gleason score, and clinical stage with improved substratification of both Gleason and groups. The new Partin Tables may help us counsel our patients regarding their likelihood of having various pathologic stages and aid in important decision making. REFERENCES 1. Greenlee RT, Hill-Harmon MB, Murray T, et al: Cancer Statistics CA Cancer J Clin 51: 15 36, Partin AW, Kattan MW, Subong MS, et al: Combination of prostate-specific antigen, clinical stage and Gleason score to predict pathological stage of localized prostate cancer: a multiinstitutional update. JAMA 277: , Kattan MW, Eastham JA, Stapleton AMF, et al: A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90: , Kattan MW, Wheeler TM, and Scardino PT: Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 17: , Agresti A: Categorical Data Analysis. New York, John Wiley & Sons, 1990, com pp Elfron B, and Tibshirani R: An Introduction to the Bootstrap. New York, Chapman & Hall, Han M, Partin AW, Pound CR, et al: Long-term biochemical disease-free and cancer-specific survival following UROLOGY 58 (6),
6 radical retropubic prostatectomy: the 15-year Johns Hopkins experience. Urol Clin North Am 28: , Han M, Snow PB, Epstein JI, et al: A neural network predicts progression for men with Gleason score 3 4 versus 4 3 tumors after radical prostatectomy. Urology 56: , Blute ML, Bergsrtalh EJ, Partin AW, et al: Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. J Urol 165: , Bauer JJ, Connelly RR, Sesterhenn IA, et al: Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy. Cancer 79: , D Amico AV, Whittington R, Malkowiez SB, et al: Combination of the preoperative level, biopsy Gleason score, percentage of positive biopsies and MRI T-stage to predict early failure in men with clinically localized prostate cancer. Urology 55: , Narayan P, Gajendran V, Taylor SP, et al: The role of transrectal ultrasound-guided-biopsy based staging, preoperative and biopsy Gleason score in prediction of final pathological diagnosis in prostate cancer. Urology 46: , Veltri RW, Miller MC, Partin AW, et al: Prediction of prostate carcinoma stage by quantitative biopsy pathology. Cancer 91: , Han M, Snow PB, Brandt JM, et al: Evaluation of artificial neural networks for the prediction of pathological stage in prostate carcinoma. Cancer 91: , Epstein JI: Gleason score 2-4 adenocarcinoma of the prostate on needle biopsy: a diagnosis that should not be made. Am J Surg Pathol 24: , UROLOGY 58 (6), 2001
Since the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors
2001 Characteristics of Insignificant Clinical T1c Prostate Tumors A Contemporary Analysis Patrick J. Bastian, M.D. 1 Leslie A. Mangold, B.A., M.S. 1 Jonathan I. Epstein, M.D. 2 Alan W. Partin, M.D., Ph.D.
More informationNIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
More informationA NEURAL NETWORK PREDICTS PROGRESSION FOR MEN WITH GLEASON SCORE 3 4 VERSUS 4 3 TUMORS AFTER RADICAL PROSTATECTOMY
ADULT UROLOGY CME ARTICLE A NEURAL NETWORK PREDICTS PROGRESSION FOR MEN WITH GLEASON SCORE 3 4 VERSUS 4 3 TUMORS AFTER RADICAL PROSTATECTOMY MISOP HAN, PETER B. SNOW, JONATHAN I. EPSTEIN, THERESA Y. CHAN,
More informationInformation Content of Five Nomograms for Outcomes in Prostate Cancer
Anatomic Pathology / NOMOGRAMS IN PROSTATE CANCER Information Content of Five Nomograms for Outcomes in Prostate Cancer Tarek A. Bismar, MD, 1 Peter Humphrey, MD, 2 and Robin T. Vollmer, MD 3 Key Words:
More informationUnderstanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD
Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics
More informationPreoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy
JBUON 2013; 18(4): 954-960 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Gleason score, percent of positive prostate and PSA in predicting biochemical
More informationconcordance indices were calculated for the entire model and subsequently for each risk group.
; 2010 Urological Oncology ACCURACY OF KATTAN NOMOGRAM KORETS ET AL. BJUI Accuracy of the Kattan nomogram across prostate cancer risk-groups Ruslan Korets, Piruz Motamedinia, Olga Yeshchina, Manisha Desai
More informationPost Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series
Post Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series E. Z. Neulander 1, Z. Wajsman 2 1 Department of Urology, Soroka UMC, Ben Gurion University,
More informationCorrelation of Gleason Scores Between Needle-Core Biopsy and Radical Prostatectomy Specimens in Patients with Prostate Cancer
ORIGINAL ARTICLE Correlation of Gleason Scores Between Needle-Core Biopsy and Radical Prostatectomy Specimens in Patients with Prostate Cancer Teng-Fu Hsieh, Chao-Hsian Chang, Wen-Chi Chen, Chien-Lung
More informationDivision of Urologic Surgery and Duke Prostate Center (DPC), Duke University School of Medicine, Durham, NC
LHRH AGONISTS: CONTEMPORARY ISSUES The Evolving Definition of Advanced Prostate Cancer Judd W. Moul, MD, FACS Division of Urologic Surgery and Duke Prostate Center (DPC), Duke University School of Medicine,
More informationOutcomes of Radical Prostatectomy in Thai Men with Prostate Cancer
Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon
More informationPrognostic Value of Surgical Margin Status for Biochemical Recurrence Following Radical Prostatectomy
Original Article Japanese Journal of Clinical Oncology Advance Access published January 17, 2008 Jpn J Clin Oncol doi:10.1093/jjco/hym135 Prognostic Value of Surgical Margin Status for Biochemical Recurrence
More informationAJCC Cancer Staging 8 th Edition. Prostate Chapter 58. Executive Committee, AJCC. Professor and Director, Duke Prostate Center
AJCC Cancer Staging 8 th Edition Prostate Chapter 58 Judd W Moul, MD, FACS Executive Committee, AJCC Professor and Director, Duke Prostate Center Duke University Durham, North Carolina Validating science.
More informationChapter 2. Understanding My Diagnosis
Chapter 2. Understanding My Diagnosis With contributions from Nancy L. Brown, Ph.D.,Palo Alto Medical Foundation Research Institute; and Patrick Swift, M.D., Alta Bates Comprehensive Cancer Program o Facts
More informationPredictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era
ORIGINAL RESEARCH Predictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era Ahva Shahabi, MPH, PhD; 1* Raj Satkunasivam, MD; 2* Inderbir S. Gill, MD; 2 Gary Lieskovsky,
More informationInvasion of the muscular wall of the seminal vesicles by prostate cancer is generally
PROSTATE CANCER Seminal Vesicle Invasion by Prostate Cancer: Prognostic Significance and Therapeutic Implications Steven R. Potter, MD,* Jonathan I. Epstein, MD,* Alan W. Partin, MD, PhD* *The James Buchanan
More informationTHE MOST COMMON definitive therapy for the treatment
Postoperative Nomogram for Disease Recurrence After Radical Prostatectomy for Prostate Cancer Michael W. Kattan, Thomas M. Wheeler, and Peter T. Scardino Purpose: Although models exist that place patients
More informationGUIDELINES ON PROSTATE CANCER
10 G. Aus (chairman), C. Abbou, M. Bolla, A. Heidenreich, H-P. Schmid, H. van Poppel, J. Wolff, F. Zattoni Eur Urol 2001;40:97-101 Introduction Cancer of the prostate is now recognized as one of the principal
More informationestimating risk of BCR and risk of aggressive recurrence after RP was assessed using the concordance index, c.
. JOURNAL COMPILATION 2008 BJU INTERNATIONAL Urological Oncology PREDICTION OF AGGRESSIVE RECURRENCE AFTER RP SCHROECK et al. BJUI BJU INTERNATIONAL Do nomograms predict aggressive recurrence after radical
More informationSupplemental Information
Supplemental Information Prediction of Prostate Cancer Recurrence using Quantitative Phase Imaging Shamira Sridharan 1, Virgilia Macias 2, Krishnarao Tangella 3, André Kajdacsy-Balla 2 and Gabriel Popescu
More informationBest Papers. F. Fusco
Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical
More informationUse of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence
Cancer Biomarkers 17 (2016) 83 88 83 DOI 10.3233/CBM-160620 IOS Press Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence Michael
More informationA Nomogram Predicting Long-term Biochemical Recurrence After Radical Prostatectomy
1254 A Nomogram Predicting Long-term Biochemical Recurrence After Radical Prostatectomy Nazareno Suardi, MD 1,2 Christopher R. Porter, MD 3 Alwyn M. Reuther, MD 4 Jochen Walz, MD 1,5 Koichi Kodama, MD
More informationPrognostic value of the Gleason score in prostate cancer
BJU International (22), 89, 538 542 Prognostic value of the Gleason score in prostate cancer L. EGEVAD, T. GRANFORS*, L. KARLBERG*, A. BERGH and P. STATTIN Department of Pathology and Cytology, Karolinska
More informationAre Prostate Carcinoma Clinical Stages T1c and T2 Similar?
Clinical Urology Are Clinical Stages T1c and T2 Similar? International Braz J Urol Vol. 32 (2): 165-171, March - April, 2006 Are Prostate Carcinoma Clinical Stages T1c and T2 Similar? Athanase Billis,
More informationA schematic of the rectal probe in contact with the prostate is show in this diagram.
Hello. My name is William Osai. I am a nurse practitioner in the GU Medical Oncology Department at The University of Texas MD Anderson Cancer Center in Houston. Today s presentation is Part 2 of the Overview
More informationthree after the most recent release in These modifications were based primarily on data from clinical, not pathological, staging [1].
. 2010 BJU INTERNATIONAL Urological Oncology PATHOLOGICAL T2 SUB-DIVISIONS AS A PROGNOSTIC FACTOR IN PROSTATE CANCER CASO ET AL. BJUI BJU INTERNATIONAL Pathological T2 sub-divisions as a prognostic factor
More informationDepartment of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara , Japan 2
Advances in Urology Volume 2012, Article ID 204215, 7 pages doi:10.1155/2012/204215 Research Article Calculated Tumor Volume Is an Independent Predictor of Biochemical Recurrence in Patients Who Underwent
More informationLong-Term Risk of Clinical Progression After Biochemical Recurrence Following Radical Prostatectomy: The Impact of Time from Surgery to Recurrence
EUROPEAN UROLOGY 59 (2011) 893 899 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by Bertrand D. Guillonneau and Karim Fizazi on
More informationPredictive Models. Michael W. Kattan, Ph.D. Department of Quantitative Health Sciences and Glickman Urologic and Kidney Institute
Predictive Models Michael W. Kattan, Ph.D. Department of Quantitative Health Sciences and Glickman Urologic and Kidney Institute Treatment for clinically localized prostate cancer Trade off: Substantial
More informationRadiation Therapy After Radical Prostatectomy
Articles ISSN 1537-744X; DOI 10.1100/tsw.2004.93 Radiation Therapy After Radical Ali M. Ziada, M.D. and E. David Crawford, M.D. Division of Urology, University of Colorado, Denver, Colorado E-mails: aziada@mednet3.camed.eun.eg
More informationRadical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience
MOLECULAR AND CLINICAL ONCOLOGY 1: 337-342, 2013 Radical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience NOBUKI FURUBAYASHI 1, MOTONOBU NAKAMURA 1,
More informationIntroduction. Key Words: high-grade prostatic intraepithelial neoplasia, HGPIN, radical prostatectomy, prostate biopsy, insignificant prostate cancer
Prostate cancer after initial high-grade prostatic intraepithelial neoplasia and benign prostate biopsy Premal Patel, MD, 1 Jasmir G. Nayak, MD, 1,2 Zlatica Biljetina, MD, 4 Bryan Donnelly, MD 3, Kiril
More informationEvaluation of prognostic factors after radical prostatectomy in pt3b prostate cancer patients in Japanese population
Japanese Journal of Clinical Oncology, 2015, 45(8) 780 784 doi: 10.1093/jjco/hyv077 Advance Access Publication Date: 15 May 2015 Original Article Original Article Evaluation of prognostic factors after
More informationjournal of medicine The new england Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy abstract
The new england journal of medicine established in 1812 july 8, 4 vol. 31 no. 2 Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy Anthony V. D Amico, M.D.,
More informationDisease-specific death and metastasis do not occur in patients with Gleason score 6 at radical prostatectomy
Disease-specific death and metastasis do not occur in patients with at radical prostatectomy Charlotte F. Kweldam, Mark F. Wildhagen*, Chris H. Bangma* and Geert J.L.H. van Leenders Departments of Pathology,
More informationGUIDELINEs ON PROSTATE CANCER
GUIDELINEs ON PROSTATE CANCER (Text update March 2005: an update is foreseen for publication in 2010. Readers are kindly advised to consult the 2009 full text print of the PCa guidelines for the most recent
More informationExternal validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer
External validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer Mathieu Roumiguié, Jean-Baptiste Beauval, Thomas Filleron*,
More informationMultiinstitutional Validation of the UCSF Cancer of the Prostate Risk Assessment for Prediction of Recurrence After Radical Prostatectomy
2384 Multiinstitutional Validation of the UCSF Cancer of the Prostate Risk Assessment for Prediction of Recurrence After Radical Prostatectomy Matthew R. Cooperberg, MD, MPH 1 Stephen J. Freedland, MD
More informationRADICAL PROSTATECTOMY IS ONE
ORIGINAL CONTRIBUTION Risk of Prostate Cancer Specific Mortality Following Biochemical Recurrence After Radical Prostatectomy Stephen J. Freedland, MD Elizabeth B. Humphreys, BS Leslie A. Mangold, MS Mario
More informationWhen PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy
When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA
More informationThe Role of the Pathologist Active Surveillance for Prostate Cancer
The Role of the Pathologist Active Surveillance for Prostate Cancer Thomas M. Wheeler, M.D. W. L. Moody, Jr., Professor and Chair Department of Pathology & Immunology Baylor College of Medicine Houston,
More informationQ&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1
Collecting Cancer Data: Prostate NAACCR 2010-2011 Webinar Series May 5, 2011 Q&A Please submit all questions concerning webinar content through the Q&A panel Overview NAACCR 2010-2011 Webinar Series 1
More informationProstate Cancer: Is There Standard Treatment? Who has prostate cancer? In this article:
Focus on CME at l Université de Montréal Prostate Cancer: Is There Standard Treatment? Pierre I. Karakiewicz, MD, FRCSC; Paul Perrotte, MD, FRCSC; Fred Saad, MD, FRCSC In this article: 1. Risk factors
More informationCorrespondence should be addressed to Taha Numan Yıkılmaz;
Advances in Medicine Volume 2016, Article ID 8639041, 5 pages http://dx.doi.org/10.1155/2016/8639041 Research Article External Validation of the Cancer of the Prostate Risk Assessment Postsurgical Score
More informationRadical prostatectomy is the most widely used treatment. Partial Sampling of Radical Prostatectomy Specimens
ORIGINAL ARTICLE Detection of Positive Margins and Extraprostatic Extension Viacheslav Iremashvili, MD, PhD,* Soum D. Lokeshwar,* Mark S. Soloway, MD,* Lise tpelaez,md,w Saleem A. Umar, MD,w Murugesan
More informationClinical Case Conference
Clinical Case Conference Intermediate-risk prostate cancer 08/06/2014 Long Pham Clinical Case 64 yo man was found to have elevated PSA of 8.65. TRUS-biopies were negative. Surveillance PSA was 7.2 in 3
More informationAccurate prediction of the biological potential of. Correlation between the Gleason Scores of Needle Biopsies and Radical Prostatectomy Specimens
Original Article 919 Correlation between the Gleason Scores of Needle Biopsies and Radical Prostatectomy Specimens Biing-Yir Shen, MD; Ke-Hung Tsui, MD; Phei-Lang Chang, MD; Cheng-Keng Chuang, MD, PHD;
More informationProstate Cancer: 2010 Guidelines Update
Prostate Cancer: 2010 Guidelines Update James L. Mohler, MD Chair, NCCN Prostate Cancer Panel Associate Director for Translational Research, Professor and Chair, Department of Urology, Roswell Park Cancer
More informationComparative Analysis Research of Robotic Assisted Laparoscopic Prostatectomy
Comparative Analysis Research of Robotic Assisted Laparoscopic Prostatectomy By: Jonathan Barlaan; Huy Nguyen Mentor: Julio Powsang, MD Reader: Richard Wilder, MD May 2, 211 Abstract Introduction: The
More informationKey words: prostatic neoplasms, risk groups, biochemical recurrence, clinical progression, prostate cancer specific mortality
JJCO Japanese Journal of Clinical Oncology Japanese Journal of Clinical Oncology, 2016, 46(8) 762 767 doi: 10.1093/jjco/hyw061 Advance Access Publication Date: 20 May 2016 Original Article Original Article
More informationPost Radical Prostatectomy Adjuvant Radiation in Patients with Seminal Vesicle Invasion - A Historical Series
Post Radical Prostatectomy Adjuvant Radiation in Patients with Seminal Vesicle Invasion - A Historical Series E. Z. Neulander 1, K. Rubinov 2, W. Mermershtain 2, Z. Wajsman 3 1 Department of Urology, Soroka
More informationProstate Case Scenario 1
Prostate Case Scenario 1 H&P 5/12/16: A 57-year-old Hispanic male presents with frequency of micturition, urinary urgency, and hesitancy associated with a weak stream. Over the past several weeks, he has
More informationNomograms for prostate cancer
Review Article NOMOGRAMS FOR PROSTATE CANCER STEPHENSON and KATTAN There are several papers in this section on various aspects of prostate cancer: predictive models, robotic radical prostatectomy in large
More informationeuropean urology 52 (2007)
european urology 52 (2007) 733 745 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Systematic Assessment of the Ability of the Number and Percentage of Positive
More informationProstate cancer staging and datasets: The Nitty-Gritty. What determines our pathological reports? 06/07/2018. Dan Berney Maastricht 2018
Prostate cancer staging and datasets: The Nitty-Gritty What determines our pathological reports? Dan Berney Maastricht 2018 Biopsy reporting. How not to do it. The TNM 8 th edition. Changes good and bad
More informationAnatomic distribution and pathologic characterization of small-volume prostate cancer (o0.5 ml) in whole-mount prostatectomy specimens
& 2005 USCAP, Inc All rights reserved 0893-3952/05 $30.00 www.modernpathology.org Anatomic distribution and pathologic characterization of small-volume prostate cancer (o0.5 ml) in whole-mount prostatectomy
More informationBJUI. Study Type Prognosis (individual cohort study) Level of Evidence 2b OBJECTIVES CONCLUSIONS
. JOURNAL COMPILATION 2008 BJU INTERNATIONAL Urological Oncology PREDICTING THE OUTCOME OF PROSTATE BIOPSY HERNANDEZ et al. BJUI BJU INTERNATIONAL Predicting the outcome of prostate biopsy: comparison
More informationin 32%, T2c in 16% and T3 in 2% of patients.
BJUI Gleason 7 prostate cancer treated with lowdose-rate brachytherapy: lack of impact of primary Gleason pattern on biochemical failure Richard G. Stock, Joshua Berkowitz, Seth R. Blacksburg and Nelson
More informationIntroduction. Original Article
bs_bs_banner International Journal of Urology (2015) 22, 363 367 doi: 10.1111/iju.12704 Original Article Prostate-specific antigen level, stage or Gleason score: Which is best for predicting outcomes after
More informationincision into an otherwise organ-confined cancer [1,5].
28 The Authors. Journal compilation 28 BJU International Original Article IMPACT ON PROGRESSION OF POSITIVE SURGICAL MARGINS AFTER RP PFITZENMAIER et al. BJUI BJU INTERNATIONAL Positive surgical margins
More informationMedical Policy Manual. Topic: Systems Pathology in Prostate Cancer Date of Origin: December 30, 2010
Medical Policy Manual Topic: Systems Pathology in Prostate Cancer Date of Origin: December 30, 2010 Section: Laboratory Last Reviewed Date: April 2014 Policy No: 61 Effective Date: July 1, 2014 IMPORTANT
More informationPredictive factors of late biochemical recurrence after radical prostatectomy
JJCO Japanese Journal of Clinical Oncology Japanese Journal of Clinical Oncology, 2017, 47(3) 233 238 doi: 10.1093/jjco/hyw181 Advance Access Publication Date: 9 December 2016 Original Article Original
More informationLong-term Oncological Outcome and Risk Stratification in Men with High-risk Prostate Cancer Treated with Radical Prostatectomy
Jpn J Clin Oncol 2012;42(6)541 547 doi:10.1093/jjco/hys043 Advance Access Publication 28 March 2012 Long-term Oncological Outcome and Risk Stratification in Men with High-risk Prostate Cancer Treated with
More informationZonal Origin of Localized Prostate Cancer Does not Affect the Rate of Biochemical Recurrence after Radical Prostatectomy
european urology 51 (2007) 949 955 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Zonal Origin of Localized Prostate Cancer Does not Affect the Rate of Biochemical
More informationPercentage of Gleason Pattern 4 and 5 Predicts Survival After Radical Prostatectomy
1967 Percentage of Gleason Pattern 4 and 5 Predicts Survival After Radical Prostatectomy Liang Cheng, MD 1,2 Darrell D. Davidson, MD, PhD 1 Haiqun Lin, MD, PhD 3 Michael O. Koch, MD 2 1 Department of Pathology
More informationAram Kim 4, Myong Kim 1, Se Un Jeong 2, Cheryn Song 1, Yong Mee Cho 2, Jae Yoon Ro 3 and Hanjong Ahn 1*
Kim et al. BMC Urology (2018) 18:7 DOI 10.1186/s12894-018-0321-z RESEARCH ARTICLE Open Access Level of invasion into fibromuscular band is an independent factor for positive surgical margin and biochemical
More informationOncologic Outcomes of Patients With Gleason Score 7 and Tertiary Gleason Pattern 5 After Radical Prostatectomy
www.kjurology.org http://dx.doi.org/10.4111/kju.2013.54.9.587 Urological Oncology Oncologic Outcomes of Patients With Gleason Score 7 and Tertiary Gleason Pattern 5 After Radical Prostatectomy Yi-Hsueh
More informationUC San Francisco UC San Francisco Previously Published Works
UC San Francisco UC San Francisco Previously Published Works Title The quantitative Gleason score improves prostate cancer risk assessment Permalink https://escholarship.org/uc/item/9wq7g6k5 Journal Cancer,
More informationRadical Prostatectomy versus Intensity Modulated Radiation Therapy in the Management of Localized Prostate Cancer
Yale University EliScholar A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine 10-19-2009 Radical Prostatectomy versus Intensity Modulated Radiation
More informationProstate-specific antigen density as a parameter for the prediction of positive lymph nodes at radical prostatectomy
1 di 10 26/12/2015 17.15 Urol Ann. 2015 Oct-Dec; 7(4): 433 437. doi: 10.4103/0974-7796.152118 PMCID: PMC4660691 Prostate-specific antigen density as a parameter for the prediction of positive lymph nodes
More informationProposed prognostic scoring system evaluating risk factors for biochemical recurrence of prostate cancer after salvage radiation therapy
Proposed prognostic scoring system evaluating risk factors for biochemical recurrence of prostate cancer after salvage radiation therapy Richard J. Lee, Katherine S. Tzou, Michael G. Heckman*, Corey J.
More informationApproximately 680,000 men are diagnosed with prostate
Prediction of Indolent Prostate Cancer: Validation and Updating of a Prognostic Nomogram E. W. Steyerberg,* M. J. Roobol, M. W. Kattan, T. H. van der Kwast, H. J. de Koning and F. H. Schröder From the
More informationPROSTATE MRI. Dr. Margaret Gallegos Radiologist Santa Fe Imaging
PROSTATE MRI Dr. Margaret Gallegos Radiologist Santa Fe Imaging Topics of today s talk How does prostate MRI work? Definition of multiparametric (mp) MRI Anatomy of prostate gland and MRI imaging Role
More informationEvaluation of the 7th American Joint Committee on Cancer TNM Staging System for Prostate Cancer in Point of Classification of Bladder Neck Invasion
Jpn J Clin Oncol 2013;43(2)184 188 doi:10.1093/jjco/hys196 Advance Access Publication 5 December 2012 Evaluation of the 7th American Joint Committee on Cancer TNM Staging System for Prostate Cancer in
More information1. INTRODUCTION. ARC Journal of Urology Volume 1, Issue 1, 2016, PP 1-7 Abstract:
ARC Journal of Urology Volume 1, Issue 1, 2016, PP 1-7 www.arcjournals.org Does the Number of Lymph Nodes Removed During Radical Prostatectomy Impact Risk of Biochemical Recurrence in Patients With Isolated
More informationHealth Screening Update: Prostate Cancer Zamip Patel, MD FSACOFP Convention August 1 st, 2015
Health Screening Update: Prostate Cancer Zamip Patel, MD FSACOFP Convention August 1 st, 2015 Outline Epidemiology of prostate cancer Purpose of screening Method of screening Contemporary screening trials
More informationEvaluation of pt2 subdivisions in the TNM staging system for prostate cancer
. JOURNAL COMPILATION 2008 BJU INTERNATIONAL Urological Oncology HONG et al. BJUI BJU INTERNATIONAL Evaluation of pt2 subdivisions in the TNM staging system for prostate cancer Sung Kyu Hong, Byung Kyu
More informationUpgrading and upstaging in prostate cancer: From prostate biopsy to radical prostatectomy
MOLECULAR AND CLINICAL ONCOLOGY 2: 1145-1149 Upgrading and upstaging in prostate cancer: From prostate biopsy to radical prostatectomy CAROLINA D'ELIA, MARIA ANGELA CERRUTO, ANTONIO CIOFFI, GIOVANNI NOVELLA,
More informationShort ( 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy
Short ( 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy Sergey Shikanov, Pablo Marchetti, Vikas Desai, Aria Razmaria, Tatjana Antic, Hikmat Al-Ahmadie*, Gregory
More informationSystems Pathology in Prostate Cancer. Description
Section: Medicine Effective Date: July 15, 2015 Subject: Systems Pathology in Prostate Cancer Page: 1 of 8 Last Review Status/Date: June 2015 Systems Pathology in Prostate Cancer Description Systems pathology,
More informationThe Actual Value of the Surgical Margin Status as a Predictor of Disease Progression in Men with Early Prostate Cancer
european urology 50 (2006) 258 265 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer The Actual Value of the Surgical Margin Status as a Predictor of Disease
More informationPathology Review for Patients with Prostate Cancer Referred to the SCCA Proton Center
Pathology Review for Patients with Prostate Cancer Referred to the SCCA Proton Center George E. Laramore, PhD, MD; Jing Zeng, MD; Li-Ming Christine Fang, MD; Jay J. Liao, MD; Kenneth J. Russell, MD Department
More informationProstate-Specific Antigen Testing of Older Men
Prostate-Specific Antigen Testing of Older Men H. Ballentine Carter, Patricia K. Landis, E. Jeffrey Metter, Lee A. Fleisher, Jay D. Pearson Background: Elevated serum prostate-specific antigen (PSA) levels
More informationClinical Study Oncologic Outcomes of Surgery in T3 Prostate Cancer: Experience of a Single Tertiary Center
Advances in Urology Volume 22, Article ID 64263, 8 pages doi:.55/22/64263 Clinical Study Oncologic Outcomes of Surgery in T3 Prostate Cancer: Experience of a Single Tertiary Center D. Milonas, G. Smailyte,
More informationProcedures Needle Biopsy Transurethral Prostatic Resection Suprapubic or Retropubic Enucleation (Subtotal Prostatectomy) Radical Prostatectomy
Prostate Gland Protocol applies to invasive carcinomas of the prostate gland. Protocol web posting date: July 2006 Protocol effective date: April 2007 Based on AJCC/UICC TNM, 6 th edition Procedures Needle
More informationOutcomes Following Negative Prostate Biopsy for Patients with Persistent Disease after Radiotherapy for Prostate Cancer
Clinical Urology Post-radiotherapy Prostate Biopsy for Recurrent Disease International Braz J Urol Vol. 36 (1): 44-48, January - February, 2010 doi: 10.1590/S1677-55382010000100007 Outcomes Following Negative
More informationSerum PSA, Gleason Score and Clinical Staging in Predicting Biochemical (PSA) Failure After Radical Prostatectomy for Carcinoma of Prostate
Article ID: WMC003222 ISSN 2046-1690 Serum PSA, Gleason Score and Clinical Staging in Predicting Biochemical (PSA) Failure After Radical Prostatectomy for Carcinoma of Prostate Corresponding Author: Mr.
More informationInsignificant Prostate Cancer in Radical Prostatectomy Specimen: TimeTrends and Preoperative Prediction
European Urology European Urology 43 (2003) 455 460 Insignificant Prostate Cancer in Radical Prostatectomy Specimen: TimeTrends and Preoperative Prediction Herbert Augustin a,b, Peter G. Hammerer a,c,*,
More informationElevated PSA. Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017
Elevated PSA Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017 Issues we will cover today.. The measurement of PSA,
More informationVictor H. W. Yeung, Yi Chiu, Sylvia S. Y. Yu, W. H. Au, and Steve W. H. Chan
The Scientific World Journal Volume 23, Article ID 5662, 4 pages http://dx.doi.org/.55/23/5662 Clinical Study Are Preoperative Kattan and Stephenson Nomograms Predicting Biochemical Recurrence after Radical
More informationS1.04 PRINCIPAL CLINICIAN G1.01 COMMENTS S2.01 SPECIMEN LABELLED AS G2.01 *SPECIMEN DIMENSIONS (PROSTATE) S2.03 *SEMINAL VESICLES
Prostate Cancer Histopathology Reporting Proforma (Radical Prostatectomy) Includes the International Collaboration on Cancer reporting dataset denoted by * Family name Given name(s) Date of birth Indigenous
More informationUndergrading and Understaging in Patients with Clinically Insignificant Prostate Cancer who Underwent Radical Prostatectomy
Clinical Urology Clinically Insignificant Prostate Cancer International Braz J Urol Vol. 36 (3): 292-299, May - June, 2010 doi: 10.1590/S1677-55382010000300005 Undergrading and Understaging in Patients
More informationChapter 6. Long-Term Outcomes of Radical Prostatectomy for Clinically Localized Prostate Adenocarcinoma. Abstract
Chapter 6 Long-Term Outcomes of Radical Prostatectomy for Clinically Localized Prostate Adenocarcinoma Vijaya Raj Bhatt 1, Carl M Post 2, Sumit Dahal 3, Fausto R Loberiza 4 and Jue Wang 4 * 1 Department
More informationPCa Commentary. Executive Summary: The "PCa risk increased directly with increasing phi values."
1101 Madison Street Suite 1101 Seattle, WA 98104 P 206-215-2490 www.seattleprostate.com PCa Commentary Volume 77 September October 2012 CONTENT Page The Prostate 1 Health Index Active Surveillance 2 A
More informationPercent Gleason pattern 4 in stratifying the prognosis of patients with intermediate-risk prostate cancer
Review Article Percent Gleason pattern 4 in stratifying the prognosis of patients with intermediate-risk prostate cancer Meenal Sharma 1, Hiroshi Miyamoto 1,2,3 1 Department of Pathology and Laboratory
More informationRare Small Cell Carcinoma in Genitourinary Tract: Experience from E-Da Hospital
E-Da Medical Journal 20;():-5 Original Article Rare Small Cell Carcinoma in Genitourinary Tract: Experience from E-Da Hospital Wei-Ting Kuo, I-Wei Chang2, Kevin Lu, Hua-Pin Wang, Tsan-Jung u, Victor C.
More informationGleason score = 8 prostate cancer: much more like Gleason score 9?
5 + 3 = 8 prostate cancer: much more like 9? Brandon A. Mahal, Vinayak Muralidhar*, Yu-Wei Chen, Toni K. Choueiri, Karen E. Hoffman, Jim C. Hu, Christopher J. Sweeney, James B. Yu**, Felix Y. Feng, Quoc-Dien
More informationSystems Pathology in Prostate Cancer
Systems Pathology in Prostate Cancer Policy Number: 2.04.64 Last Review: 8/2014 Origination: 8/2010 Next Review: 8/2015 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will not provide coverage
More informationPSA Screening and Prostate Cancer. Rishi Modh, MD
PSA Screening and Prostate Cancer Rishi Modh, MD ABOUT ME From Tampa Bay Went to Berkeley Prep University of Miami for Undergraduate - 4 years University of Miami for Medical School - 4 Years University
More information